Inside Bio-Rad Laboratories’ Robust Revenue Growth Projection for 2017

On March 13, 2017, Bio-Rad Laboratories (BIO) provided a long-term, currency-neutral revenue growth target of around 3%–5%.

Margaret Patrick - Author

May 22 2017, Updated 12:36 p.m. ET


Robust revenue growth

On March 13, 2017, Bio-Rad Laboratories (BIO) provided a long-term, currency-neutral revenue growth target of around 3%–5%. The company has also projected currency-neutral YoY (year-over-year) revenue growth of around 4% for fiscal 2017.

For fiscal 2017, Wall Street analysts have projected that Bio-Rad Laboratories’ total revenues will be around $2.1 billion, which would represent a YoY growth of ~3.2%.

In 2017, peers PerkinElmer (PKI), Danaher (DHR), and Thermo Fisher Scientific (TMO) are expected to report revenues of around $2.2 billion, $17.9 billion, and $19.6 billion, respectively.

Article continues below advertisement
Article continues below advertisement

Revenue trends in 1Q17

In 1Q17, autoimmune products, blood typing, western blotting, and Droplet Digital PCR (polymerase chain reaction) products contributed significantly to Bio-Rad’s revenue growth. While the company’s sales were slightly lower in the US and Japan, the impact was partly offset by higher demand for Bio-Rad’s products in Europe, China, and Asia-Pacific.

Some orders from the European market were pulled forward ahead of the company’s deployment of its new SAP system. However, even after excluding this effect, the company witnessed a healthy YoY rise in sales from European markets on a currency neutral basis.

Bio-Rad’s gross margin

Despite the rise in revenues, Bio-Rad Laboratories witnessed a drop in gross margins in 1Q17, mainly due to a $10-million, one-time expense related to the acquisition of RainDance Technologies. The company’s gross margin also suffered due to the increasing costs associated with the set-up of its new supply chain model in Europe. These negative effects were partly offset by a favorable product mix and reduced amortization expenses.

Notably, the Vanguard Small-Cap ETF (VB) has about 0.14% of its total portfolio holdings in Bio-Rad Laboratories.

Continue to the next part for a closer look at Bio-Rad Laboratories’ margin projections.


Latest Bio-Rad Laboratories Inc News and Updates

    Opt-out of personalized ads

    © Copyright 2024 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.